Integral Diagnostics Reports 26% Revenue Growth and $22M Profit in FY26

Strong Financial Performance Backed by Merger Synergies

Integral Diagnostics (ASX:IDX) has reported a standout FY26, with revenues soaring 26% to $788.6 million and statutory profit after tax leaping 677% to $22 million. The company’s operating NPAT climbed 50% to $47.4 million, while operating EBITDA rose 30% to $164.8 million, lifting the margin by 80 basis points to 20.9%. These results reflect robust organic growth complemented by $14 million-plus in synergies from the Capitol Health merger completed in December 2024.

Merger integration is largely complete, with ongoing procurement efficiencies and operational cost leverage underpinning margin expansion. Net debt remains stable at $298.9 million, with the net debt to EBITDA ratio improving to 2.3x from 2.6x in FY25, signalling disciplined financial management despite ongoing capital investment.

Dividend Boost and Leadership Transition

The Board declared a fully franked final dividend of 6 cents per share, up 50% on the prior year, bringing total dividends for FY26 to 9.3 cents per share, up from 6.5 cents in FY25. This reflects confidence in the company’s cash flow generation and balance sheet strength.

Leadership changes marked the year with long-serving CEO Dr Ian Kadish and CFO Craig White retiring in August 2026. Jason Martinez, with over 20 years in diagnostic imaging, stepped in as CEO, and Jenny Martin was appointed CFO, bringing fresh operational and financial expertise to guide the next phase of growth.

Operational Highlights and Growth Investments

Integral Diagnostics served over 1.7 million patients and performed more than 4 million examinations across 142 clinics in Australia and New Zealand. The company’s teleradiology platform, IDXt, expanded reporting volumes by over 30%, now covering every Australian state and New Zealand, supported by 143 reporting radiologists.

Investment in growth continued with $21 million spent on new greenfield and brownfield sites, including new specialist orthopaedic practices at Eastwood Private Hospital in South Australia and Maroochy Private Hospital in Queensland, as well as clinics in Wangaratta and Launceston. The company positions itself to benefit from MRI deregulation in July 2027, aiming to leverage its scale and specialist expertise.

Sustainability and Governance Advances

Integral Diagnostics made significant strides in sustainability, achieving a 93% reduction in Scope 1 and 2 greenhouse gas emissions against its FY24 baseline, primarily through 100% renewable electricity procurement in Australia. The company set a target to reduce absolute Scope 1 and market-based Scope 2 emissions by 42% by 2030.

Governance enhancements included strengthening the Board’s skills matrix to incorporate sustainability and climate-related expertise, and advancing clinical governance frameworks. The company reported excellent patient satisfaction with a Net Promoter Score of 81 and maintained a strong focus on workforce development amid industry-wide labour shortages.

Challenges and Incentive Outcomes

While financial results were strong, the FY24 Long-Term Incentive (LTI) performance rights lapsed due to unmet performance conditions, reflecting the company’s rigorous performance standards. Workforce shortages remain a challenge, prompting initiatives such as radiologist registrar engagement and in-house training programs for sonographers and radiographers.

Looking forward, Integral Diagnostics aims to continue disciplined growth, margin improvement, and operational efficiency, supported by strategic capital expenditure guidance of $50 million to $60 million for FY27.